Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia is under clinical development by China Immunotech (Beijing) Biotechnology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GlobalData
Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Buy the report

Related Company Profiles

View All

Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia overview

Gene therapy is under development for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia. It is administered through intravenous route. The therapeutic candidate comprises of genetically modified T-cells to express dual synthetic T cell antigen receptors (STAR-T cells). It acts by targeting cells expressing CD19 and CD22.

For a complete picture of Gene Therapy to Target CD19 and CD22 for Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.